Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
Sherief Abd-Elsalam, Ossama Ashraf Ahmed, Noha O Mansour, Doaa H Abdelaziz, Marwa Salama, Mohamed Hassan Ahmed Fouad, Shaimaa Soliman, Ahmed Mohamed Naguib, Mohamed Sayed Hantera, Ibrahim S Ibrahim, Mohamed Torky, Hany M Dabbous, Mohamed Samir Abd El Ghafar, Enas A Abdul-Baki, Mohammed Elhendawy
The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.21-0606
To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30-60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P , 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P 5 0.469). The mortality rate was comparable between the two groups (P 5 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P 5 0.039, 0.003, 0.001, and , 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low-and middle-income countries when other effective options are scarce.
R E T R A C T E D
References
Bansal, Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis, Front Med
Beigel, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Beigel, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Dabbous, Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Arch Virol
Goldman, Remdesivir for 5 or 10 days in patients with severe COVID-19, N Engl J Med
Gordon, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J Biol Chem
Horby, Dexamethasone in hospitalized patients with covid-19, N Engl J Med
Kalil, Baricitinib plus remdesivir for hospitalized adults with COVID-19, N Engl J Med
Olender, Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care, Clin Infect Dis,
doi:10.1093/cid/ciaa1041
Pizzorno, Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia, Cell Reports Med
Rezagholizadeh, Khiali, Sarbakhsh, Entezari-Maleki, Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis, Eur J Pharmacol
Sharifpour, Rangaraju, Liu, C-reactive protein as a prognostic indicator in hospitalized patients with COVID-19, PLoS One
Soni, Gopalakrishnan, Vaishya, Prabu, D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases, Diabetes Metab Syndr
Spinner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Twreafc, Tw, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
Uzunova, Filipova, Pavlova, Vekov, Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2, Biomed Pharmacother,
doi:10.1016/j.biopha.2020.110668
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wang, Wang, Wang, Lau, Zhang et al., COVID-19 in early 2021: current status and looking forward, Signal Transduct Target Ther